What is Merck & Co.'s market cap?

Merck & Co. (MRK) has a market capitalization of $311.17B and trades on NYSE.

What is Merck & Co.'s revenue and profitability?

Merck & Co. generated $65.8B in trailing twelve-month revenue with net income of $8.9B, representing a net margin of 13.6%. Gross margin stands at 73.9%, with free cash flow of $14.1B. These figures are based on the Q1 2026 filing.

Who are Merck & Co.'s competitors?

Merck & Co.'s key competitors include Bristol-Myers Squibb, Zoetis Inc., Sanofi, and others. These companies compete in similar markets and product categories.

Who does Merck & Co. partner with?

Merck & Co.'s notable partners include AstraZeneca, Eisai Co., Ltd., Pfizer Inc., and others.

What subsidiaries does Merck & Co. have?

Merck & Co.'s subsidiaries include Cidara Therapeutics, Inc., Allflex Livestock Intelligence, Sure Petcare.

Where is Merck & Co. headquartered?

Merck & Co. is headquartered in United States of America. It has been publicly traded since 1949.

Merck & Co.

MRK

Merck & Co., Inc. is a global healthcare company focused on the discovery, development, and manufacturing of innovative health solutions.

Market cap

$311.17B+53.1%

Revenue$65.8B+2.9%

Net income$8.9B-48.8%

Free cash flow$14.1B-17.2%

EPS (diluted)$3.56-48.2%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 30, 2026

Revenue$16.3BBeat by $439.7M EPS-$1.28Beat by $0.19

Read the full report

Next report

Aug 4, 2026 (In 3 weeks)

Revenue estimate$16.4B

EPS estimate$2.12

Financials

Q1 2026

Income statement

See full

Revenue$16.3B+4.9%

Gross profit$12.1B-0.2%

Net income-$4.2B-183%

EPS (diluted)-$1.72-186%

Balance sheet

See full

Cash & equivalents$5.4B-38.2%

Total debt$49.1B+35.8%

Total equity$45.9B-5.1%

Total assets$128.69B+11.8%

Cash flow

See full

Operating cash flow$3.9B+56.7%

CapEx$991.0M-25.4%

Free cash flow$2.9B+150%

Valuation & ratios

Valuation

See full

Market cap$311.17B+53.1%

Enterprise value$354.88B+53.0%

P/E34.8×+22.4×

P/S4.7×+1.5×

Profitability

See full

Gross margin73.9%-2.5pp

Net margin13.6%-13.7pp

FCF margin21.5%-5.2pp

Returns & leverage

See full

Return on equity19%-20.3pp

Debt / equity1.1×+0.3×

Current ratio1.3×-0.1×

Competitors

By market cap

Johnson & Johnson$634.06B+68.9%

AbbVie$446.54B+33.6%

Merck & Co.$311.17B+53.1%

Pfizer$137.07B-5.0%

Bristol-Myers Squibb$117.50B+23.1%

Zoetis$31.5B-55.6%

Opko Health$1.1B-1.3%

Puma Biotechnology$413.8M+133%

By revenue growth

AbbVie+9.5%

Johnson & Johnson+7.9%

Merck & Co.+2.9%

Zoetis+2.6%

Bristol-Myers Squibb+1.8%

Pfizer+1.4%

Opko Health-15.7%

By net margin

Zoetis27.79%+0.9pp

Johnson & Johnson21.83%-2.6pp

Pfizer15.65%+6.3pp

Bristol-Myers Squibb15.01%+3.8pp

Merck & Co.13.59%-13.7pp

AbbVie5.79%-1.5pp

Opko Health-36.64%-31.0pp

Profile

Merck & Co., Inc. is a global healthcare company focused on the discovery, development, and manufacturing of innovative health solutions. The company delivers a diverse portfolio of prescription medicines, biologic therapies, vaccines, and animal health products to address unmet medical needs. Its core value proposition centers on research-driven innovation to treat human disorders and manage the health of livestock and companion animals.

Competitive position

A leading global research-based biopharmaceutical company with a dominant position in oncology and vaccines, supported by a significant animal health business.

GeographiesUnited States, European Union, Japan, China, Emerging Markets

Customer segmentsHealthcare Providers, Government Entities, Veterinary Clinics, Agricultural Producers

Business modelResearch and Development, Manufacturing, B2B Distribution, Licensing and Alliances

SuppliersRaw material suppliers, Intermediate chemical manufacturers, Academic research institutions, Third-party manufacturing partners

CustomersDrug wholesalers (e.g., McKesson, AmerisourceBergen), Pharmacy benefit managers, Public health systems, Retail pharmacies, Veterinary distributors

CountryUnited States of America

Listed1949

CEORobert Davis

SectorHealthcare

IndustryDrug Manufacturers - General

Websitemerck.com

FilingsSEC EDGAR

Ask your AI about Merck & Co..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Merck & Co.'s market cap?: Merck & Co. (MRK) has a market capitalization of $311.17B and trades on NYSE.
What is Merck & Co.'s revenue and profitability?: Merck & Co. generated $65.8B in trailing twelve-month revenue with net income of $8.9B, representing a net margin of 13.6%. Gross margin stands at 73.9%, with free cash flow of $14.1B. These figures are based on the Q1 2026 filing.
Who are Merck & Co.'s competitors?: Merck & Co.'s key competitors include Bristol-Myers Squibb, Zoetis Inc., Sanofi, and others. These companies compete in similar markets and product categories.
Who does Merck & Co. partner with?: Merck & Co.'s notable partners include AstraZeneca, Eisai Co., Ltd., Pfizer Inc., and others.
What subsidiaries does Merck & Co. have?: Merck & Co.'s subsidiaries include Cidara Therapeutics, Inc., Allflex Livestock Intelligence, Sure Petcare.
Where is Merck & Co. headquartered?: Merck & Co. is headquartered in United States of America. It has been publicly traded since 1949.